FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washir

gton, D.C. 20549	ОМ

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  ANG ROBERT					2. Issuer Name <b>and</b> Ticker or Trading Symbol Vor Biopharma Inc. [ VOR ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner  Officer (give title Other (specify			
(Last) (First) (Middle) C/O VOR BIOPHARMA INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2022					7	X Officer (give title Officer (spe below) below)  President and CEO				
100 CAMBRIDGEPARK DRIVE, SUITE 400															
(Street)	IDGE M	IA	02140	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)			Line)	X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(9	State)	(Zip)									Person			
		Ta	ble I - Non-D	erivati	ve Se	curities	s Ac	quired, D	isposed o	of, or Be	neficially	Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D		e	action Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a			(msu. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)			Transa Code	ansaction Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership ct (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	n(s)	
Employee Stock Option (right to buy)	\$8.63	02/01/2022		A		376,000		(1)	01/31/2032	Common Stock	376,000	\$0.00	376,000	) D	

## **Explanation of Responses:**

1. This option vests over four years in equal monthly installments beginning on February 1, 2022.

## Remarks:

/s/ Robert Ang

02/03/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.